Durvalumab After chemoRadioTherapy for NSCLC patients Study design
The study will include 50 patients with PD-L1 positive and 50 with PD-L1 negative tumours.
Tumour biopsies, blood samples, urine, and feces will be collected prior to chemoradiation, after chemoradiation and during immunotherapy and at time of progression (if the patient progresses). For a subset of patients, immuno-PET will be perfomed. The patients will be followed for 2 years after end of immunotherapy.
